1-9 of 9
Katharina Lechner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Martin Hutchings, Michael J. Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, William Townsend, Francesc Bosch, Nancy L. Bartlett, Guillaume Cartron, Herve Ghesquieres, Roch Houot, Harriet S. Walter, Fritz Offner, Natalie Dimier, Candice Jamois, Lance Smith, Sylvia Herter, Denis Sahin, Abiraj Keelara, Koorosh Korfi, Jeremy Gallien, Marie-Helene Wasmer, Heather Hinton, Matt Whayman, Isabel Prieto, Georgios Kazantzidis, Katharina Lechner, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 990.
https://doi.org/10.1182/blood-2024-200096
Published: 2024
Journal Articles

CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Koorosh Korfi, Sabine Wilson, Zhiwen Jiang, Ailsa Christiansen, Sreenath Krishnan, Candice Jamois, Annika Blank, Alexandra Epp, Abraham Silva, Philip Knuckles, Joanne Hayward, Johannes Sam, Katharina Lechner, Natalie Dimier, Paolo F. Caimi, Lorenzo Falchi, Giuseppe Gritti, Franck Morschhauser, Martin Hutchings, Michael J. Dickinson, Carmelo Carlo-Stella
Journal: Blood
Blood (2024) 144 (Supplement 1): 644.
https://doi.org/10.1182/blood-2024-201406
Published: 2024
Journal Articles

BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL

Michael J. Dickinson, Martin Hutchings, Franck Morschhauser, Carmelo Carlo-Stella, Lorenzo Falchi, Paolo F. Caimi, Natalie Dimier, Lance Smith, Matt Whayman, Johannes Sam, Abiraj Keelara, Koorosh Korfi, Candice Jamois, Jeremy Gallien, Nicole Martin, Iris Martinez Quetglas, Heather Hinton, Isabel Prieto, Francesca Michielin, Katharina Lechner, Giuseppe Gritti
Journal: Blood
Blood (2024) 144 (Supplement 1): 3123.
https://doi.org/10.1182/blood-2024-205544
Published: 2024
Journal Articles

Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

Candice Jamois, Koorosh Korfi, Sylvia Herter, Sabine Wilson, Sreenath Krishnan, Marie-Helene Wasmer, Isabel Prieto, Heather Hinton, Wouter Driessen, Georgios Kazantzidis, Denis Sahin, Akiko Tagawa, Natalie Dimier, Katharina Lechner
Journal: Blood
Blood (2024) 144 (Supplement 1): 4180.
https://doi.org/10.1182/blood-2024-201466
Published: 2024
Journal Articles

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Jenny Thom, Sylvia Herter, Guy Georges, Koorosh Korfi, Martin Lechmann, Miro Julian Eigenmann, Daniel Marbach, Candice Jamois, Katharina Lechner, Sreenath M. Krishnan, Brenda Gaillard, Joana Marinho, Sven Kronenberg, Leo Kunz, Sabine Wilson, Stefanie Briner, Samuel Gebhardt, Ahmet Varol, Birte Appelt, Valeria Nicolini, Dario Speziale, Miriam Bez, Esther Bommer, Jan Eckmann, Carina Hage, Florian Limani, Silvia Jenni, Anne Schoenle, Marine Le Clech, Jean-Baptiste Pierre Vallier, Sara Colombetti, Marina Bacac, Stephan Gasser, Christian Klein, Pablo Umaña
Journal: Blood
Blood (2024) 143 (21): 2152–2165.
https://doi.org/10.1182/blood.2023023381
Published: 2024
Includes: Supplemental data
Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Koorosh Korfi, Ailsa Christiansen, Zhiwen Jiang, Sabine Wilson, Samuel Tracy, Annika Blank, Sylvia Herter, Natalie Dimier, Bruno Gomes, Pablo Umana, Herve Ghesquieres, Roch Houot, Fritz Offner, Harriet Walter, Nancy L. Bartlett, Guillaume Cartron, Michael Dickinson, William Townsend, Giuseppe Gritti, Francesc Bosch Albareda, Franck Morschhauser, Martin Hutchings, Carmelo Carlo-Stella, Katharina Lechner
Journal: Blood
Blood (2023) 142 (Supplement 1): 3017.
https://doi.org/10.1182/blood-2023-173677
Published: 2023
Journal Articles

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Martin Hutchings, MD PhD, Fritz C. Offner, MD PhD, Francesc Bosch, MD PhD, Giuseppe Gritti, MD PhD, Carmelo Carlo-Stella, MD, Harriet Walter, William Townsend, MRCP,MDFRCPath, Franck Morschhauser, MD PhD, Guillaume Cartron, MD PhD, Hervé Ghesquieres, MD PhD, Sophie de Guibert, MD, Sylvia Herter, PhD, Koorosh Korfi, PhD, Veronica Craine, Sarah Louise Mycroft, Matt Whayman, Claudia Mueller, Natalie Dimier, PhD, Tom Moore, MBChB, Sara Belli, Martin Kornacker, MD, Katharina Lechner, Michael Dickinson, DMed Sci
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-136571
Published: 2020
Journal Articles

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Karthik Ramasamy, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Myo Htut, MD, Rakesh Popat, Michaela Liedtke, MD, Sascha A Tuchman, MD, Jacob P. Laubach, MD, Cristina Gasparetto, MD, Asher A. Chanan-Khan, MD, Mark Hertzberg, MBBS PhDFRACP FRCPA, Mark Demario, MD MPH, Eveline Nueesch, PhD, Evelyne Chesne, PhD, Izolda Franjkovic, PhD, Katharina Lechner, Martin Kornacker, MD, Hearn Jay Cho, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–14.
https://doi.org/10.1182/blood-2020-136392
Published: 2020
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt
Journal: Blood
Blood (2019) 134 (Supplement_1): 2871.
https://doi.org/10.1182/blood-2019-123978
Published: 2019